• Wondering if IQVIA Holdings at around US$171.50 is offering value right now, or if you are paying up for growth expectations that may already be in the price.
• The stock is roughly flat over the past week, down around 3% over the past month and down 23.9% year to date, yet it is still up 24.9% over the past year. This can leave investors questioning whether the recent weakness signals changing risk sentiment or just normal volatility.
• Recent headlines have focused on IQVIA Holdings' role in pharmaceutical data, clinical research services and technology solutions for life sciences clients, giving more visibility to its position across trial support and real world data analytics. This context helps frame why sentiment around the stock can shift as investors weigh contract pipelines, regulatory developments and demand for outsourced research services.
• IQVIA Holdings currently scores a valuation check score of 6/6. The rest of this article will walk through what that means across different valuation methods while keeping one more powerful perspective on valuation for the end.

Approach 1: IQVIA Holdings Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and discounting them back to today using a required return. It is essentially asking what IQVIA Holdings' future cash generation is worth in today's dollars.

For IQVIA Holdings, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $2.06b. Analyst inputs and Simply Wall St extrapolations project Free Cash Flow rising to $3.06b by 2030, with detailed yearly estimates and discounted values provided for the period from 2026 through 2035.

On this basis, the DCF model arrives at an estimated intrinsic value of $314.78 per share compared with the current share price of about $171.50. That gap implies the stock trades at roughly a 45.5% discount to the model's estimate of fair value, which is a sizable margin.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests IQVIA Holdings is undervalued by 45.5%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: IQVIA Holdings Price vs Earnings

For a profitable company, the P/E ratio is a useful way to see how much you are paying for each dollar of earnings. It ties the share price directly to the bottom line, which is what ultimately supports long term returns.

What counts as a “normal” P/E depends on how fast earnings are expected to grow and how risky those earnings are. Higher growth or lower perceived risk can justify a higher multiple, while lower growth or higher risk usually calls for a lower one.

IQVIA Holdings currently trades on a P/E of 20.67x. This sits below the Life Sciences industry average P/E of 35.53x and below the peer group average of 41.06x, suggesting the stock is valued more conservatively than many peers on this metric alone.

Simply Wall St’s Fair Ratio for IQVIA Holdings is 21.99x. This is a proprietary estimate of what the P/E might be given factors such as earnings growth, industry, profit margins, market cap and company specific risks. Because it is tailored to the company, it can be more informative than a simple comparison with industry or peer averages.

Comparing the Fair Ratio of 21.99x with the actual P/E of 20.67x points to IQVIA Holdings trading below that fair level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your IQVIA Holdings Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as a simple story you build around IQVIA Holdings that links your view on its AI adoption, clinical trial demand, regulation and balance sheet to a concrete forecast for revenue, earnings and margins, then to a Fair Value you can compare with the current price.

On Simply Wall St’s Community page, Narratives let you set this story driven Fair Value in an accessible way and keep it updated automatically when new information such as earnings, guidance changes or AI related partnerships is added to the platform.

For IQVIA Holdings, one investor might lean toward the higher Fair Value of about US$290.00, seeing data scale, AI platforms and real world evidence demand as supportive for future earnings. Another might align with the lower Fair Value of about US$186.12, focusing more on debt levels, pricing pressure, data privacy risks and competition. By comparing each Narrative’s Fair Value to the market price you can decide whether the stock looks closer to a buy, hold or sell in your own framework.

Do you think there's more to the story for IQVIA Holdings? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.